Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Overview | 10 | 1 |
| Therapeutics Development | 11 | 4 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Stage of Development | 11 | 1 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Therapy Area | 12 | 1 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Indication | 13 | 2 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Companies | 17 | 5 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Products under Development by Universities/Institutes | 22 | 2 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Therapeutics Assessment | 24 | 5 |
| Assessment by Monotherapy/Combination Products | 24 | 1 |
| Assessment by Mechanism of Action | 25 | 1 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 1 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Companies Involved in Therapeutics Development | 29 | 22 |
| Aerie Pharmaceuticals, Inc. | 29 | 1 |
| Aptose Biosciences Inc. | 30 | 1 |
| Astex Pharmaceuticals, Inc. | 31 | 1 |
| AstraZeneca Plc | 32 | 1 |
| Bristol-Myers Squibb Company | 33 | 1 |
| Celon Pharma Sp. z o.o. | 34 | 1 |
| Concert Pharmaceuticals, Inc. | 35 | 1 |
| CTI BioPharma Corp. | 36 | 1 |
| Daiichi Sankyo Company, Limited | 37 | 1 |
| Eli Lilly and Company | 38 | 1 |
| Genentech, Inc. | 39 | 1 |
| Gilead Sciences, Inc. | 40 | 1 |
| Incyte Corporation | 41 | 1 |
| Merck &Co., Inc. | 42 | 1 |
| Nerviano Medical Sciences S.r.l. | 43 | 1 |
| Nippon Shinyaku Co., Ltd. | 44 | 1 |
| Novartis AG | 45 | 1 |
| SOM Innovation Biotech SL | 46 | 1 |
| Theravance Biopharma, Inc. | 47 | 1 |
| Tolero Pharmaceuticals, Inc. | 48 | 1 |
| Tragara Pharmaceuticals, Inc. | 49 | 1 |
| Vectura Group Plc | 50 | 1 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Drug Profiles | 51 | 65 |
| AC-410 Drug Profile | 51 | 1 |
| AR-13154 Drug Profile | 52 | 1 |
| AT-9283 Drug Profile | 53 | 2 |
| AZD-1480 Drug Profile | 55 | 2 |
| baricitinib Drug Profile | 57 | 7 |
| BVB-808 Drug Profile | 64 | 1 |
| CHZ-868 Drug Profile | 65 | 1 |
| CPL-407105 Drug Profile | 66 | 1 |
| CPL-40722 Drug Profile | 67 | 1 |
| CTP-543 Drug Profile | 68 | 1 |
| lestaurtinib Drug Profile | 69 | 1 |
| MA-2014 Drug Profile | 70 | 1 |
| momelotinib dihydrochloride Drug Profile | 71 | 5 |
| MRLB-11055 Drug Profile | 76 | 1 |
| NMSP-113 Drug Profile | 77 | 1 |
| NMSP-953 Drug Profile | 78 | 1 |
| NS-018 Drug Profile | 79 | 1 |
| pacritinib Drug Profile | 80 | 11 |
| ruxolitinib phosphate Drug Profile | 91 | 13 |
| SAR-317461 Drug Profile | 104 | 1 |
| Small Molecule to Inhibit JAK2 for Leukemia Drug Profile | 105 | 1 |
| Small Molecules to Inhibit JAK2 for Cancer Drug Profile | 106 | 1 |
| Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders Drug Profile | 107 | 1 |
| Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders Drug Profile | 108 | 1 |
| Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms Drug Profile | 109 | 1 |
| TD-1473 Drug Profile | 110 | 1 |
| TG-02 Drug Profile | 111 | 3 |
| TP-0413 Drug Profile | 114 | 1 |
| VR-588 Drug Profile | 115 | 1 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Dormant Projects | 116 | 6 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Discontinued Products | 122 | 2 |
| Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) Featured News &Press Releases | 124 | 18 |
| Jun 23, 2016: FDA Grants Breakthrough Therapy Designation for Incyte s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD) | 124 | 1 |
| Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera | 124 | 1 |
| Jun 09, 2016: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs | 125 | 1 |
| Jun 09, 2016: Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) | 126 | 2 |
| Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor | 128 | 1 |
| Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting | 129 | 4 |
| Jun 07, 2016: Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology | 133 | 1 |
| Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis | 134 | 1 |
| May 19, 2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting | 135 | 1 |
| May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings | 136 | 1 |
| May 19, 2016: Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata | 137 | 1 |
| May 04, 2016: Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata | 138 | 1 |
| May 03, 2016: Parkinson's disease pathogenesis reduced in rat model by a cell-signaling inhibitor drug | 138 | 2 |
| Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment | 140 | 1 |
| Apr 13, 2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting | 140 | 2 |
| Appendix | 142 | 2 |
| Methodology | 142 | 1 |
| Coverage | 142 | 1 |
| Secondary Research | 142 | 1 |
| Primary Research | 142 | 1 |
| Expert Panel Validation | 142 | 1 |
| Contact Us | 142 | 1 |
| Disclaimer | 143 | 1 |